Medicine and Dentistry
Cervicectomy
66%
Uterine Cancer
66%
Niraparib
50%
Cervical Cancer
48%
Olaparib
33%
Ovarian Cancer
33%
Interleukin 33
33%
Safety Assessment
33%
Minimally Invasive Procedure
33%
Bevacizumab
33%
Malignant Ascites
33%
Mean Platelet Volume
33%
Clinical Feature
33%
Ovarian Reserve
33%
DNA Damage
33%
Lymph Node Metastasis
33%
Recurrent Ovarian Cancer
33%
Lymphocyte
33%
Uncoupling Protein 2
33%
Mesenchymal-Epithelial Transition
33%
Obstetrics
33%
PARP Inhibitor
33%
Prospective Study
33%
Paracentesis
29%
Hormone Determination
29%
Overall Survival
20%
Tertiary Lymphoid Structure
16%
Anemia
16%
Blood Sampling
16%
Thrombocytopenia
16%
Chemotherapy
13%
Progression Free Survival
12%
Recurrent Disease
12%
Hypoxia
11%
Cancer Cell
11%
Metastatic Carcinoma
11%
Lanatoside C
9%
Infusion
9%
Adverse Event
8%
Homologous Recombination
8%
Treatment Interruption
8%
Lymphoid Cell
8%
Retrospective Study
8%
Fatality
8%
Malignant Neoplasm
8%
Nausea
8%
Blood Toxicity
8%
Maintenance Therapy
8%
Retrospective Cohort Study
8%
Serous Carcinoma
8%
Keyphrases
Peritumoral Lymphocytes
33%
DNA Damage-inducible Transcript 4
33%
Bevacizumab
33%
Ovarian Clear Cell Carcinoma
33%
Survival Outcomes
33%
Radical Trachelectomy
33%
Potential Biomarkers
33%
Heavily Treated
33%
Ovarian Reserve
33%
Malignant Ascites
33%
Recurrent Ovarian Cancer
33%
DDIT4
33%
Mean Platelet Volume
33%
Small EVs
33%
Let-7 Family
33%
Vaccinia-related Kinase
33%
Hormone Levels
29%
Anti-Mllerian Hormone
29%
Bevacizumab Therapy
26%
Paracentesis
20%
Digital Analysis
16%
Niraparib
16%
Palliative Approach
13%
Conventional Chemotherapy
13%
Epithelial Ovarian Cancer
13%
Half-dose
13%
Random Forest Regression
11%
Performance Prediction
11%
Homologous Recombination Deficiency
11%
Lanatoside C
9%
Controlled Ovarian Stimulation
8%
Blood Toxicity
8%
Informed Consent
6%
Progressive Disease
6%
Cancer Center
6%
Adverse Events
6%
Medical Expenses
6%
Terminal Stage
6%
Ovarian Cancer
6%
Clinical Data
6%
Simple Trachelectomy
6%
Fertility-preserving Treatment
6%
Platinum Resistance
6%
Heavily Pretreated
6%
Interventional Study
6%
Clinical Benefit
6%
Tai Chi
6%
Ascitic Fluid
6%
Specific Treatment
6%
Lymphorrhea
6%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Niraparib
50%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
33%
Olaparib
33%
Interleukin 33
33%
Bevacizumab
33%
Safety Assessment
33%
Malignant Ascites
33%
Clinical Feature
33%
Vaccinia
33%
microRNA
33%
Thrombocytopenia
16%
Anemia
16%
Disease
11%
Lanatoside C
9%
Recurrent Disease
8%
Adverse Event
8%
Retrospective Study
8%
Nausea
8%
Blood Toxicity
8%
Aubergine
8%
Carcinoma
8%
Nanoparticle
6%
Western Blot
6%
Female Genital Tract Cancer
6%
Therapeutic Effect
6%